 TOR Serine-Threonine Kinases
"TOR Serine-Threonine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that TACROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.
| Descriptor ID |
D058570
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.931 D12.776.476.925
|
| Concept/Terms |
TOR Serine-Threonine Kinases- TOR Serine-Threonine Kinases
- Kinases, TOR Serine-Threonine
- Serine-Threonine Kinases, TOR
- TOR Serine Threonine Kinases
- FKBP12-Rapamycin Associated Protein
- Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Associated Protein
- Protein, FKBP12-Rapamycin Associated
- FKBP12-Rapamycin Complex-Associated Protein
- Complex-Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Complex Associated Protein
- Protein, FKBP12-Rapamycin Complex-Associated
- Mechanistic Target of Rapamycin Protein
- TOR Kinases
- mTOR Serine-Threonine Kinases
- Kinases, mTOR Serine-Threonine
- Serine-Threonine Kinases, mTOR
- mTOR Serine Threonine Kinases
- RAFT-1 Protein
- Protein, RAFT-1
- RAFT 1 Protein
- Rapamycin Target Protein
- Protein, Rapamycin Target
- Target Protein, Rapamycin
- Target of Rapamycin Proteins
- Rapamycin Proteins Target
- FK506 Binding Protein 12-Rapamycin Associated Protein 1
- FK506 Binding Protein 12 Rapamycin Associated Protein 1
- mTOR Protein
- Protein, mTOR
|
Below are MeSH descriptors whose meaning is more general than "TOR Serine-Threonine Kinases".
Below are MeSH descriptors whose meaning is more specific than "TOR Serine-Threonine Kinases".
This graph shows the total number of publications written about "TOR Serine-Threonine Kinases" by people in this website by year, and whether "TOR Serine-Threonine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2004 | 0 | 3 | 3 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 2 | 2 | | 2008 | 0 | 4 | 4 | | 2009 | 0 | 8 | 8 | | 2010 | 1 | 7 | 8 | | 2011 | 4 | 4 | 8 | | 2012 | 6 | 4 | 10 | | 2013 | 0 | 6 | 6 | | 2014 | 5 | 4 | 9 | | 2015 | 1 | 5 | 6 | | 2016 | 8 | 4 | 12 | | 2017 | 8 | 0 | 8 | | 2018 | 1 | 5 | 6 | | 2019 | 4 | 3 | 7 | | 2020 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "TOR Serine-Threonine Kinases" by people in Profiles.
-
O'Leary EM, Tian Y, Nigdelioglu R, Witt LJ, Cetin-Atalay R, Meliton AY, Woods PS, Kimmig LM, Sun KA, Gökalp GA, Mutlu GM, Hamanaka RB. TGF-ß Promotes Metabolic Reprogramming in Lung Fibroblasts via mTORC1-dependent ATF4 Activation. Am J Respir Cell Mol Biol. 2020 11; 63(5):601-612.
-
Tjota M, Chen H, Parilla M, Wanjari P, Segal J, Antic T. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study. Am J Surg Pathol. 2020 07; 44(7):943-954.
-
Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, Kraven LM, Obeidat M, Li X, Ng M, Braybrooke R, Molina-Molina M, Hobbs BD, Putman RK, Sakornsakolpat P, Booth HL, Fahy WA, Hart SP, Hill MR, Hirani N, Hubbard RB, McAnulty RJ, Millar AB, Navaratnam V, Oballa E, Parfrey H, Saini G, Whyte MKB, Zhang Y, Kaminski N, Adegunsoye A, Strek ME, Neighbors M, Sheng XR, Gudmundsson G, Gudnason V, Hatabu H, Lederer DJ, Manichaikul A, Newell JD, O'Connor GT, Ortega VE, Xu H, Fingerlin TE, Bossé Y, Hao K, Joubert P, Nickle DC, Sin DD, Timens W, Furniss D, Morris AP, Zondervan KT, Hall IP, Sayers I, Tobin MD, Maher TM, Cho MH, Hunninghake GM, Schwartz DA, Yaspan BL, Molyneaux PL, Flores C, Noth I, Jenkins RG, Wain LV. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020 03 01; 201(5):564-574.
-
El Andaloussi A, Al-Hendy A, Ismail N, Boyer TG, Halder SK. Introduction of Somatic Mutation in MED12 Induces Wnt4/ß-Catenin and Disrupts Autophagy in Human Uterine Myometrial Cell. Reprod Sci. 2020 03; 27(3):823-832.
-
Jung J, Zhang Y, Celiku O, Zhang W, Song H, Williams BJ, Giles AJ, Rich JN, Abounader R, Gilbert MR, Park DM. Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma. Cancer Res. 2019 10 15; 79(20):5218-5232.
-
Chen Q, Deng X, Hu X, Guan S, He M, Wang Y, Wei B, Zhang J, Zhao H, Yao W, Jin F, Liu Y, Chen J, Olapade OI, Wu H, Wei M. Breast Cancer Risk-Associated SNPs in the mTOR Promoter Form De Novo KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. Mol Cancer Res. 2019 11; 17(11):2244-2256.
-
Liu W, Zhuang J, Jiang Y, Sun J, Prinz RA, Sun J, Jiao X, Xu X. Toll-like receptor signalling cross-activates the autophagic pathway to restrict Salmonella Typhimurium growth in macrophages. Cell Microbiol. 2019 12; 21(12):e13095.
-
Dobyns WB, Mirzaa GM. Megalencephaly syndromes associated with mutations of core components of the PI3K-AKT-MTOR pathway: PIK3CA, PIK3R2, AKT3, and MTOR. Am J Med Genet C Semin Med Genet. 2019 12; 181(4):582-590.
-
Yan G, Ru Y, Yan F, Xiong X, Hu W, Pan T, Sun J, Zhang C, Wang Q, Li X. MIIP inhibits the growth of prostate cancer via interaction with PP1a and negative modulation of AKT signaling. Cell Commun Signal. 2019 05 15; 17(1):44.
-
Waise TMZ, Rasti M, Duca FA, Zhang SY, Bauer PV, Rhodes CJ, Lam TKT. Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production. Nat Commun. 2019 02 12; 10(1):714.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|